Sistema de Información Esencial en Terapéutica y Salud


Última actualización: 20/2/2021
SIETES contiene 93212 citas

 1 a 13 de 13 
Presentar resultados
Seleccionar todas
1.Enlace a cita original Cita con resumen
Waxmonsky JG, Pelham W 3rd, Campa A, Waschbusch DA, Li T, Marshall R, Babocsai L, Humphery H, Gnagy E, Swanson J, Hanc T, Fallahazad N, Pelham WE 4th. A randomized controlled trial of interventions for growth suppression in children with attention-deficit/hyperactivity disorder treated with central nervous system stimulants. J Am Acad Child Adolesc Psychiatry 2019:29 de agosto. [Ref.ID 103191]
3. Cita con resumen
Xie Y, Bowe B, Li T, Xian H, Yan Y, Al-Aly Z. Risk of death among users of proton pump inhibitors: a longitudinal observational cohort study of United States veterans. BMJ Open 2017;7:e015735. [Ref.ID 101661]
4. Cita con resumen
Rouse B, Cipriani A, Shi Q, Coleman AL, Dickersin K, Li T. Network meta-analysis for clinical practice guidelines: a case study, on first-line medical therapies for primary open-angle glaucoma. Ann Intern Med 2016;164:674-82. [Ref.ID 100297]
5. Cita con resumen
Xie Y, Bowe B, Li T, Xian H, Balasubramanian S, Al-Aly Z. Proton pump inhibitors and risk of incident CKD and progression to ESRD. J Am Soc Nephrol 2016:14 de abril. [Ref.ID 100161]
6.Tiene citas relacionadas Cita con resumen
Hu Y, Lu S, Song Z, Want W, Hao P, Li J, Zhang X, Yen H-L, Shi B, Li T, Guan W, Xu L, Liu Y, Wang S, Zhang XS, Tian D, Zhu Z, He J, Huang K, Chen H, Zheng L, Li X, Ping J, Kang B, Xi X, Zha L, Li Y, Zhang Z, Peiris M, Yuan Z. Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance. Lancet 2013;381:2273-9. [Ref.ID 95761]
8. Cita con resumen
Murad MH, Drake MT, Mullan RJ, Mauk KF, Stuart LM, Lane MA, Abu Elnour NO, Erwin PJ, Hazem A, Puhan MA, Li T, Montori VM. Clinical review. Comparative effectiveness of drug treatments to prevent fragility fractures: a systematic review and network meta-analysis. J Clin Endocrinol Metab 2012;97:1871-80. [Ref.ID 92114]
9. Cita con resumen
van Dam RM, Li T, Spiegelman D, Franco OH, Hu FB. Combined impact of lifestyle factors on mortality: prospective cohort study in US women. BMJ 2008;337:742-5. [Ref.ID 84012]
10. Cita con resumen
Kremer JM, Genant HK, Moreland LW, Russell AS, Emery P, Abud-Mendoza C, Szechinski J, Li T, Ge Z, Becker J-C, Wethovens R. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis. A randomized trial. Ann Intern Med 2006;144:865-76. [Ref.ID 77364]
11. Cita con resumen
Genovese MC, Becker J-C, Schiff MH, Luggen ME, Sherrer Y, Kremer JM, Birbara C, Box J, Natarajan K, Nuamah I F, Li T, Aranda R, Hagerty DT, Dougados M. Abatacept for rhematoid arthritis refractory to tumor necrosis factor alfa inhibitor. N Engl J Med 2005;353:1114-23. [Ref.ID 74789]
12.Tiene citas relacionadas Cita con resumen
Hu FB, Willett WC, Li T, Stampfer MJ, Colditz GA, Manson JE. Adiposity as compared with physical activity in predicting mortality among women. N Engl J Med 2004;351:2694-703. [Ref.ID 72283]
13.Tiene citas relacionadas
Treasure J, Collier D, Arranz MJ, Li T, Mupita D. Selective serotonin reuptake inhibitors in anorexia nervosa. Authors' reply. Lancet 1997;350:1033-4. [Ref.ID 35449]
Seleccionar todas
 1 a 13 de 13